- European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc PFE and BioNTech SE BNTX.
- One site, located in Frankfurt, is operated by Sanofi-Aventis Deutschland GmbH, part of Sanofi SA SNY. The other in Hameln is operated by Siegfried Hameln GmbH. Both sites will manufacture the finished product.
- These sites will provide up to 50 million additional doses in 2021.
- Read Next: EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines.
- Price Action: PFE shares are down 1.29% at $45.91, while BNTX stock is up 3.88% at $349.29 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
